As Ceva finalises its latest 2020-2025 strategic plan, the company recently made the following significant changes to its leadership team.

Véronique Kodjo has been appointed to the newly created position of Global Manufacturing and Supply Chain Director and member of the Executive Committee of Ceva. She arrives from Boehringer Ingleheim, where she was a member of the animal health executive committee and has a proven track record of leading strategic transformation in manufacturing, quality and supply chain in the complex animal health arena.

Pascal Anjot, previously head of the Pharmaceutical business unit will assume the new role of Innovation and Research Director, with responsibility for both vaccine, pharmaceutical and bio-pharmaceutical portfolio development. He remains a member of Ceva’s management board.

Commenting on the changes, Ceva’s Chairman & CEO, Dr. Marc Prikazsky said: “As we enter the year of Ceva’s 20th anniversary, we face new set of challenges resulting from the tremendous growth we have enjoyed in previous years. Anticipating the future needs of our customers and our society as a whole has always been our key driver. Veronique will bring a fresh pair of eyes and invaluable experience to ensuring that our industrial strategy matches this growth. At the same time, given the scientific convergence between research in biology and pharmaceuticals, Pascal will ensure that we focus our efforts on developing major products for the future”.